Navigating Your Weight Loss Journey: Understanding What is Therapeutic Dose of Wegovy

Last reviewed: July 2, 2026

Last updated: July 2, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

There is no single "therapeutic dose" of Wegovy. The Wegovy prescribing information defines a set of maintenance dosages, and which one applies to a given person depends on the indication being treated, how the medication is tolerated, and the prescriber's judgment. For the injection, the label describes escalation from a 0.25 mg starting dosage through 0.5 mg, 1 mg and 1.7 mg before a maintenance dosage is reached; for weight reduction in adults the recommended maintenance dosage is 2.4 mg once weekly, with a labeled maximum of 7.2 mg once weekly. For the tablet, the recommended maintenance dosage is 25 mg once daily. Those are the label's numbers, not a recommendation for any individual reader, and only a prescriber working from your full clinical picture can say which applies to you.

What the Label Defines as a Maintenance Dosage

Wegovy's labeling does not treat "maintenance dosage" as one number. It assigns different maintenance dosages to different approved uses. For reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight, the label lists 2.4 mg once weekly as recommended, with 1.7 mg once weekly as an alternative. For reducing excess body weight and maintaining weight reduction long term in adults, 2.4 mg is the recommended maintenance dosage, with 1.7 mg also listed and escalation to a labeled maximum of 7.2 mg once weekly available. For pediatric patients aged 12 years and older with obesity, the recommended maintenance dosage is 2.4 mg, with 1.7 mg listed as an alternative. For noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advanced liver fibrosis, the label describes 2.4 mg once weekly, with a reduction to 1.7 mg once weekly where needed.

That structure is the actual answer to the question. A dose is "therapeutic" in relation to a specific indication and a specific patient, not in the abstract. The same 2.4 mg appears across several indications, but the evidence supporting it, the population studied, and the endpoints measured are different in each case.

Why the Label Builds In a Stepwise Escalation

Wegovy injection is not initiated at its maintenance dosage. The labeled schedule moves through 0.25 mg for four weeks, then 0.5 mg, 1 mg and 1.7 mg at four-week intervals before maintenance. The stated purpose of that structure is to reduce gastrointestinal adverse reactions, which are the most common adverse events across the semaglutide program.

This is why asking "what is the therapeutic dose" can be misleading in practice. For most of the first four months on the injection, a person is by definition not at a maintenance dosage. That period is not a failure of treatment; it is the design of the labeling. How quickly anyone moves through it, and whether they move through it at all, is a clinical decision made by the prescriber based on tolerability, and it is documented on the pharmacy label that comes with the prescription.

The 7.2 mg Maintenance Dosage and What the Trial Showed

On March 19, 2026 the FDA approved Wegovy HD, a 7.2 mg dose, for reduction of excess body weight and long-term weight maintenance in adults with obesity or overweight with at least one weight-related condition. It was the fourth approval under the agency's National Priority Voucher program.

The supporting phase 3b evidence is the STEP UP trial, which randomly assigned 1,407 adults with a body mass index of 30 kg/m² or greater and without diabetes to semaglutide 7.2 mg, 2.4 mg, or placebo for 72 weeks. Mean bodyweight change was −18.7% with 7.2 mg versus −15.6% with 2.4 mg and −3.9% with placebo. Gastrointestinal adverse events were reported in 70.8% of the 7.2 mg group compared with 61.2% at 2.4 mg and 42.8% on placebo. A higher labeled maximum is not a better dosage for everyone; it is an additional option with a measurably different tolerability profile.

The Tablet Uses Entirely Different Numbers

Wegovy is now available as an oral tablet as well as an injection, and the two forms share almost no numbers. The tablet's labeled dosage forms are 1.5 mg, 4 mg, 9 mg and 25 mg, and the recommended maintenance dosage is 25 mg orally once daily. The injection's dosage forms run from 0.25 mg to 7.2 mg per weekly dose.

The gap has nothing to do with potency in the ordinary sense. Semaglutide is a peptide, and peptides are poorly absorbed from the gut, so an oral formulation has to deliver far more drug to achieve comparable systemic exposure. Anyone comparing milligram figures between the tablet and the injection is comparing two different things.

Why "Therapeutic Dose" Is the Wrong Frame

The phrase implies a threshold that separates working from not working. Clinical trials do not describe semaglutide that way. In the pivotal 68-week STEP 1 trial of 1,961 adults without diabetes, mean change in body weight from baseline was −14.9% with once-weekly semaglutide 2.4 mg. That is a group mean. Individual results within any trial arm spread widely above and below it.

Response varies for reasons that include adherence, tolerability, concurrent medications, baseline metabolic health, and behavioral factors, and none of those are captured by a milligram number. A dosage that is well tolerated and sustained often produces more benefit over a year than a higher one that is abandoned in month three.

Where Compounded Semaglutide Sits in This

Compounded semaglutide is not an FDA-approved finished product, and the FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed. It is prepared by a licensed pharmacy pursuant to a prescription for an individual patient.

Practically, this means Wegovy's labeled dosage table does not transfer to a compounded preparation. Concentrations, volumes and units may differ, and the FDA has specifically reported adverse events, some requiring hospitalization, that may relate to dosing errors with compounded semaglutide, arising both from patient self-administration and from healthcare provider miscalculation. The only authoritative source for what a specific prescription contains is that prescription's own pharmacy label, read alongside the prescriber who wrote it.

The Decision Belongs to Your Prescriber

Nothing in this article is a dosing instruction. Wegovy is a prescription medication with a boxed warning regarding thyroid C-cell tumors and labeled warnings covering pancreatitis, gallbladder disease, acute kidney injury, severe gastrointestinal reactions and pulmonary aspiration during anesthesia, among others. Those warnings are the reason dose selection is a medical act.

What a reader can usefully bring to that conversation is context: what other medications they take, what they have tolerated before, what the goal of treatment actually is, and what tradeoff between speed and side effects they are willing to make. The prescriber supplies the number.

Frequently Asked Questions

What is the maintenance dosage of Wegovy injection?

The prescribing information assigns maintenance dosages by indication rather than giving one universal number. For reducing excess body weight in adults, 2.4 mg once weekly is the recommended maintenance dosage, with 1.7 mg also listed and a labeled maximum of 7.2 mg once weekly available. For cardiovascular risk reduction and for noncirrhotic MASH, the label describes 2.4 mg once weekly, with 1.7 mg as an alternative. Your prescriber determines which applies to you.

Why does Wegovy start at a lower dose than the maintenance dosage?

The label describes a stepwise escalation through 0.25 mg, 0.5 mg, 1 mg and 1.7 mg at four-week intervals before a maintenance dosage is reached. The stated purpose is to reduce gastrointestinal adverse reactions, which are the most commonly reported adverse events in the semaglutide program. That means most people are not at a maintenance dosage for roughly the first four months, which is the design of the labeling rather than a sign that treatment is not working.

Is the 7.2 mg dose better than 2.4 mg?

It produced more weight reduction and more side effects. In the 72-week STEP UP trial of 1,407 adults with obesity and without diabetes, mean bodyweight change was minus 18.7% with semaglutide 7.2 mg versus minus 15.6% with 2.4 mg and minus 3.9% with placebo. Gastrointestinal adverse events occurred in 70.8% of the 7.2 mg group versus 61.2% at 2.4 mg. Whether that tradeoff makes sense for an individual is a clinical judgment.

Why is the Wegovy tablet 25 mg when the injection is only 2.4 mg?

Because the two forms are absorbed completely differently. Semaglutide is a peptide, and peptides are poorly absorbed through the gastrointestinal tract, so an oral formulation must deliver substantially more drug to reach comparable systemic exposure. The tablet's labeled strengths are 1.5 mg, 4 mg, 9 mg and 25 mg, with 25 mg once daily as the recommended maintenance dosage. Milligram figures cannot be compared across the two forms.

Does compounded semaglutide use the same doses as Wegovy?

Not necessarily. Compounded semaglutide is not an FDA-approved finished product, and the FDA does not review compounded drugs for safety, effectiveness or quality before marketing. Concentrations and units can differ from the approved product, and the FDA has reported adverse events, some requiring hospitalization, that may relate to dosing errors with compounded semaglutide. The pharmacy label on your specific prescription and your prescriber are the only authoritative sources.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.